research Association of 5-α reductase inhibitors and sexual dysfunction: A RADAR report
Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
Search
for
Sort by
Research
540-570 / 1000+ results 
research Bioavailability File: Bicalutamide
Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
research Exploring the Use of Topical Tofacitinib in Pediatric Alopecia Totalis
Topical tofacitinib may help regrow hair in children with alopecia totalis.
research Dual effects of 5α-reductase inhibitor dutasteride on androgenetic alopecia and acne vulgaris
Dutasteride improved both hair loss and acne in two young men.
research DecisionDx‐Melanoma and Sentinel Lymph Node Biopsy
research Vemurafenib-induced pityriasis amiantacea: a case report
Vemurafenib can cause scalp issues but can be managed without changing the dose.
research The Thyroid Hormone Analogue KB2115 (Eprotirome) Prolongs Human Hair Growth (Anagen) Ex Vivo
KB2115 (eprotirome) can safely extend the hair growth phase without damaging cells or changing hair color.
research ISID1116 – Novel androgen receptor degrader for androgenetic alopecia (AGA) application
research 27604 Response to baricitinib in the treatment of patients with early and late onset alopecia areata in the phase 2 portion of BRAVE-AA1 randomized controlled trial
Baricitinib was effective in treating both early and late onset alopecia areata.
research Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
research Design, synthesis and anti-tumor evaluation of novel thiohydantoin congeners as androgen receptor antagonists with in vivo study.
A new compound, 3a, effectively fights prostate cancer better than finasteride.
research Finasteride with Doxazosin to Reduce BPH Progression
research USE OF UPADACITINIB IN 2 CASES OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
research Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention
Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.
research Docetaxel and permanent alopecia
Some breast cancer patients treated with high-dose docetaxel may experience permanent hair loss.
research 151 High effectiveness of tildrakizumab over 52 weeks in patients with or without nail psoriasis: results from the phase IV POSITIVE Austrian subset
Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.
research The Use of Oral Dutasteride, Minoxidil, and Finasteride for Treating Endocrine Therapy-Induced Hair Loss from Breast Cancer Treatment: A Case Series Study
Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
research POS0080 TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE
Tofacitinib is a promising treatment for children with rheumatic diseases.
research 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib
Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
research PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION
Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
research Provenge is Talk of GU Malignancies Congress
Provenge extends prostate cancer survival by about 4 months.
research Effect of the frequency of injection on the clinical responses of postmenopausal women to testosterone enanthate with estradiol valerate
Injecting 2 ml of TEEV every 4 weeks is better because it has the same benefits but fewer side effects.
research The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.
research Prostate cancer update: 2007
2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
research Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia
Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.
research Dutasteride for Androgenetic Alopecia—Words of Caution
Dutasteride's effect on hair loss treatment is uncertain and should be used cautiously.
research Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
research Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
Baricitinib works better in adolescents than adults for treating severe alopecia areata.